|
|
Article: Mathematical Model Based on Clinical Findings From Cervarix(TM), GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination Could Reduce Cervical Cancers by up to 80%.
- Article from:
- PR Newswire
- Article date:
- October 30, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LONDON, England and RIXENSART, Belgium, October 30 /PRNewswire-FirstCall/ -- Mathematical model projections predict that vaccinating all 11-13 year old girls with Cervarix(TM), GSK's cervical cancer candidate vaccine, has the potential to reduce the incidence of cervical cancer by up to 80%, based on available clinical data.[1] The projections model was constructed in two stages. In the first, vaccination with GSK's cervical cancer candidate vaccine -- which has shown excellent protection against the two most cancer-causing HPV types, 16 and 18[2] -- accounted for a projected 74% reduction of cervical cancer in France. This constituted the base-case analysis of this ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cervarix for protection against cervical ...
South African Medical Journal;
July 1, 2007 ;
700+ words
... ... GlaxoSmithKline's (GSK) cervical cancer candidate vaccine, Cervarix, demonstrated ... found that GSK's cervical cancer candidate vaccine induced a strong ... study of GSK's cervical cancer candidate vaccine. The study was ...
|
|